Stomach Vs. Thigh Vs. Arm: What the Clinical Data Really Says About Wegovy Injection Sites

Uncover essential information surrounding Stomach Vs. Thigh Vs. Arm: What the Clinical Data Really Says About Wegovy Injection Sites.

Novo Nordisk evaluated the pharmacokinetic properties of subcutaneous semaglutide across three standardized anatomical zones: the abdomen, the front of the thighs, and the outer area of the upper arm. The primary metrics measured were total area under the plasma concentration-time curve (AUC), which reflects total bioavailability, and maximum serum concentration (Cmax).

The results settled the question of systemic potency. Total bioavailability differences across the three anatomical locations fell well within standard bioequivalence parameters. Total drug exposure remains stable regardless of where the pen clicks. A patient injecting 2.4 mg into the thigh absorbs the same cumulative dose of semaglutide over seven days as a patient injecting into the periumbilical region.

Slight variations do emerge in the semaglutide absorption rate. Subcutaneous adipose tissue in the abdominal wall typically possesses higher microvascular blood flow compared to the outer thigh. This vascular difference can cause the drug to reach its maximum concentration slightly faster after an abdominal injection. While that slight difference in peak timing does not change cumulative weekly drug exposure, it directly explains why patients report disparate physical reactions depending on where they inject.